Format

Send to

Choose Destination
Clin Cancer Res. 2016 Feb 1;22(3):757-64. doi: 10.1158/1078-0432.CCR-14-3100. Epub 2015 Oct 16.

The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.

Author information

1
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon. Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, Oregon.
2
Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon. Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, Oregon.
3
Division of Hematology, Department of Medicine, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, California.
4
McFarland Clinic, Ames, Iowa.
5
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
6
Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon. Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon. tynerj@ohsu.edu.

Abstract

PURPOSE:

Colony-stimulating factor 3 receptor (CSF3R) mutations have been identified in the majority of chronic neutrophilic leukemia (CNL) and a smaller percentage of atypical chronic myeloid leukemia (aCML) cases. Although CSF3R point mutations (e.g., T618I) are emerging as key players in CNL/aCML, the significance of rarer CSF3R mutations is unknown. In this study, we assess the importance of the CSF3R T640N mutation as a marker of CNL/aCML and potential therapeutic target.

EXPERIMENTAL DESIGN:

Sanger sequencing of leukemia samples was performed to identify CSF3R mutations in CNL and aCML. The oncogenicity of the CSF3R T640N mutation relative to the T618I mutation was assessed by cytokine independent growth assays and by mouse bone marrow transplant. Receptor dimerization and O-glycosylation of the mutants was assessed by Western blot, and JAK inhibitor sensitivity was assessed by colony assay.

RESULTS:

Here, we identify a CSF3R T640N mutation in two patients with CNL/aCML, one of whom was originally diagnosed with MDS and acquired the T640N mutation upon evolution of disease to aCML. The T640N mutation is oncogenic in cellular transformation assays and an in vivo mouse bone marrow transplantation model. It exhibits many similar phenotypic features to T618I, including ligand independence and altered patterns of O-glycosylation--despite the transmembrane location of T640 preventing access by GalNAc transferase enzymes. Cells transformed by the T640N mutation are sensitive to JAK kinase inhibition to a similar degree as cells transformed by CSF3R T618I.

CONCLUSIONS:

Because of its similarities to CSF3R T618I, the T640N mutation likely has diagnostic and therapeutic relevance in CNL/aCML.

PMID:
26475333
PMCID:
PMC4738027
DOI:
10.1158/1078-0432.CCR-14-3100
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center